Minimal residual disease in autologous hematopoietic harvests from breast cancer patients

A Spyridonidis, W Bernhardt, S Fetscher, D Behringer… - Annals of oncology, 1998 - Elsevier
A Spyridonidis, W Bernhardt, S Fetscher, D Behringer, R Mertelsmann, R Henschler
Annals of oncology, 1998Elsevier
The increasing use of high-dose chemotherapy with autologous hematopoietic
transplantation for the treatment of solid malignancies has raised concern about the role of
tumor cells contaminating the grafts. Minimal residual disease (MRD) in autologous grafts
has became a dynamic and intensively studied field in oncology. This review discusses the
current status of MRD in breast cancer autografts and presents existing data on detection
methodology, clinical relevance, biologic characteristics and purging techniques.
Summary
The increasing use of high-dose chemotherapy with autologous hematopoietic transplantation for the treatment of solid malignancies has raised concern about the role of tumor cells contaminating the grafts. Minimal residual disease (MRD) in autologous grafts has became a dynamic and intensively studied field in oncology. This review discusses the current status of MRD in breast cancer autografts and presents existing data on detection methodology, clinical relevance, biologic characteristics and purging techniques.
Elsevier